September 30, 2021 12:34 PM EDTUpdated October 1, 07:45 AM

New House bill aims to shore up US API production in response to pandemic shortages

Josh Sullivan

Amidst heavy demand for drugs and vaccines throughout the world, a new House bill, dubbed the PREPARE ACT of 2021, would create a national stockpile …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New House bill aims to shore up US API production in response to pandemic shortages

Josh Sullivan

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

New House bill aims to shore up US API pro­duc­tion in re­sponse to pan­dem­ic short­ages

Josh Sullivan

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

New House bill aims to shore up US API production in response to pandemic shortages

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma